Table 1.
Ongoing and planned combination clinical trials involving venetoclax.
| Clinicaltrials.gov identifier | Disease state(s) | Partner drug(s) | Phase |
|---|---|---|---|
| NCT03000660 | R/R AL Amyloidosis | Dexamethasone | I |
| NCT02756897 | CLL; R/R or high risk, treatment-naive | Ibrutinib | II |
| NCT02951117 | R/R MM | ABBV-838 (ADC against CS-1); dex | IB |
| NCT02899052 | R/R MM | Carfilzomib; dex | II |
| NCT02966782 | MDS (HMA failures) | Azacitidine | IB |
| NCT02993523 | AML (elderly; treatment-naïve) | Azacitidine (vs. aza plus placebo) | III |
| NCT02942290 | MDS (previously untreated) | Azacitidine (vs. aza alone) | II |
| NCT02877550 | FL, treatment-naive | Obinutuzumab | I |
| NCT02758665 | Previously untreated CLL with TP53 deletion and/or mutation | Ibrutinib plus obinutuzumab | II |
| NCT02992522 | R/R B-NHL | Lenalidomide plus obinutuzumab | I |
| NCT02670044 | R/R AML | Cobimetinib (MEK inhibitor) or idasanutlin (HDM2 inhibitor) | IB/II |
| NCT02611323 | R/R FL or DLBCL | Obinutuzumab plus polatuzumab vedotin (ADC against CD79b) | Ib/II |
| NCT02987400 | R/R DLBCL | Obinutuzumab | II |
| NCT02910583 | Treatment-naïve CLL/SLL | Ibrutinib | II |
| NCT02755597 | MM (proteasome inhibitor candidates) | Bortezomib plus dex (vs. bortezomib plus dex plus placebo) | III |
| NCT02956382 | R/R FL | Ibrutinib | I/II |
| NCT01671904 | CLL; R/R or previously untreated | BR or bendamustine plus obinutuzumab | IB |
| NCT02950051 | Fit patients with previously untreated CLL without del17p or TP53 mutation | Rituximab or obinutuzumab or obinutuzumab plus ibrutinib (vs. FCR/BR without venetoclax) | III |
| NCT02427451 | CLL; R/R or previously untreated | Ibrutinib plus obinutuzumab | I/II |
| NCT02287233 | AML (elderly; treatment-naïve) | LDAC | I/II |
| NCT02419560 | R/R MCL | Ibrutinib | I/IB |
Abbreviations: R/R, relapsed/refractory; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; ADC, antibody-drug conjugate; MDS, myelodysplastic syndrome; HMA, hypomethylating agent; AML, acute myeloid leukemia; FL, follicular lymphoma; B-NHL, B-cell non Hodgkin’s lymphoma; DLBCL, diffuse large B-cell lymphoma; MEK, mitogen activated protein kinase kinase; HDM2, human double minute 2; SLL, small lymphocytic lymphoma; LDAC, low dose cytarabine; MCL, mantle cell lymphoma; BR, bendamustine plus rituximab; FCR, fludarabine, cyclophosphamide and rituximab; dex, dexamethasone; aza, azacitidine.